Animal-Derived Component-Free Policy

Ancillary materials derived from biological origin can introduce risks to the process and final ATMP product, including transmission of viruses.
Using animal-derived component-free cytokines:

• Ensures maximum safety of the ATMP, no animal or human-derived components are part of any of our cytokine products.

• Reduces variables associated with animal-derived components.

• Makes time-consuming and expensive viral safety studies obsolete, thereby bringing a significant economic benefit.

We follow a strict animal-derived component-free (ADCF) policy to ensure maximum safety of our preclinical and GMP cytokines. As a result, no animal or human-derived components are part of any of our cytokine products.

The large majority of our cytokines is produced in a dedicated animal-free facility (ADCF Level 2). These cytokines have never been exposed to animal components or byproducts. Very few cytokines produced in the segregated animal-derived components (ADC) production area require either the use of ADC in the production process or a mammalian expression system to allow proper functional expression (ADCF Level 1). To ensure maximum safety we provide documented evidence of viral and prion safety.